News
CMS Extends Deadlines for Medicaid Drug Pricing Model Participation
The Centers for Medicare & Medicaid Services (CMS) has extended several key application deadlines for drug manufacturers and states to…
Heart Procedure Outperforms Medication for Atrial Fibrillation, Study Finds
A minimally invasive heart procedure developed by Boston Scientific has been shown to significantly outperform standard drug therapy in treating…
AstraZeneca Commits $405 Million UK Investment Following U.S.-UK Pharma Pricing Agreement
London — AstraZeneca will invest £300 million ($405 million) in the United Kingdom, marking a renewed commitment to its home…
AbbVie Surpasses Q1 Expectations as New Immunology Drugs Offset Humira Decline
Chicago — AbbVie reported first-quarter results that exceeded Wall Street expectations, driven by strong demand for its newer immunology therapies…
GE HealthCare Cuts Full-Year Profit Forecast as Inflation and Tariffs Weigh on Margins
Chicago — GE HealthCare lowered its full-year profit outlook after reporting first-quarter results impacted by rising inflation and tariff-related costs,…
Align Technology Surpasses Q1 Expectations, Announces $200 Million Share Buyback
San Jose — Align Technology reported first-quarter results that exceeded Wall Street expectations, supported by sustained demand for its Invisalign…
Biogen Beats Q1 Profit Estimates as Rare Disease Portfolio Gains Momentum
Boston — Biogen reported stronger-than-expected first-quarter results, driven by growing demand for its newer rare-disease and Alzheimer’s treatments, sending its…
Regeneron Pharmaceuticals Beats Q1 Estimates on Dupixent Strength; Shares Fall on Eylea Concerns
New York — Regeneron Pharmaceuticals reported better-than-expected first-quarter revenue and profit, driven by strong demand for its blockbuster eczema treatment…
GSK Shares Fall Despite Strong Q1 as Investors Flag One-Off Boosts
London — Shares of GSK dropped more than 8% on Wednesday, as investors questioned the quality of the company’s first-quarter…
Eli Lilly Investors Seek Early Signals on Foundayo Launch as Obesity Drug Race Intensifies
New York — Investors in Eli Lilly are expected to focus less on first-quarter financial results and more on early…